Your browser does not support JavaScript or it may be disabled!
rediff.com
 India As It Happens
Rediff Labs will showcase innovative products that rediff is working on behind the scenes.
News   |   Images
NEWS ON MOBILE
Get Realtime News
on your webpage

About 392 results for "biocon"

Biocon expects to list Syngene by July: Kiran Mazumdar Shaw
India Infoline

Kiran Mazumdar-Shaw is No 2 on global 'Medicine Maker Power Li...

Kiran Mazumdar-Shaw, Chairperson of biopharmaceutical major Biocon Ltd, has been ranked No. 2 on 'The Medicine Maker Power List' 2015, an index of the 100 most influential people across the globe in the field of medicine. Mazumdar-Shaw appears ... Business Standard India, 1 week ago
[x]  

90 images for biocon

NDTV, 6 days ago
India Infoline, 2 weeks ago
India Infoline, 2 weeks ago
Med India, 3 weeks ago
Money Today, 3 weeks ago
NDTV Profit, 3 weeks ago
NewsR.in, 3 weeks ago
Sify, 3 weeks ago
MSN India, 2 weeks ago
Livemint.com, 3 weeks ago
Livemint.com

Biocon Q4 net profit increases

Biocon Ltd, a biopharmaceutical company, has reported that net profit for the fourth quarter ended March 31, 2015 was INR2.01 billion, or INR10.0 per share, compared to INR1.13 billion, or INR5.7 per share, for the same quarter ended March 31, 2014.
 Individual.com6 days ago Biocon Q4 PAT surges to Rs. 201.54 crores  Equity Bulls3 weeks ago Biocon posts Rs201 crore net profit in Q4  Livemint.com3 weeks ago Biocon shares gain 2% on Q4 results  Hindu Business Line3 weeks ago
[x]  
Business Standard

Biocon-Mylan Programs Make Progress: PEG-G-CSF and Adalimumab enter Phase 3 clinical trials; Patient recruitment for one Insulin Glargine Phase 3 study completed

Release date- 08052015 - Biocon, Asia's premier biotechnology company, announced today that it has made clinical progress in its partnered programs with Mylan. The partnership has a strong portfolio of generic insulin analogs and biosimilars ...
 Pharmacy Choice1 week ago Biocon begins phase-3 trials for cancer drug  Business Standard India2 weeks ago Biocon updates on clinical progress of generic insulin analogs and biosimilars  Capital Market2 weeks ago Biocon-Mylan programmes make clinical progress  Financial Express2 weeks ago
[x]  
Bangalore Mirror

Museum adoption issue will be resolved, says Deshpande

7 corporate houses have offered to adopt tourist spots in state After Biocon chief Kiran Mazumdar Shaw expressed disappointment over bureaucratic hurdles to adopt the Visvesvaraya Industrial Technological Museum, the tourism department has taken up ...
 Bangalore Mirror2 days ago Shaw cold-storages museum adoption project after Centre's cold response  Bangalore Mirror1 week ago
India Infoline

Details dribble out on Biocon's Syngene unit ahead of India IPO

A contract research organization's initial public offering in India will be closely watched not only for signs of demand but also as to whether the local market may look anew at its broad biomedical sector. CRO Syngene had a record quarter, ...
 Fierce CRO2 weeks ago Biocon`s CRO Arm Syngene seeks approval for IPO  HDFC Securities2 weeks ago Biocon arm Syngene seeks approval for IPO  India Infoline2 weeks ago Biocon's CRO Arm Syngene seeks approval for IPO  Capital Market2 weeks ago
[x]  
Business Standard

Biocon subsidiary Syngene to float public issue

Pharma major Biocon Ltd, today said it has filed papers with the market regulator for floating a public issue for its R&D subsidiary, Syngene International Ltd. ''Syngene International Ltd, a subsidiary of the company has proposed public issue of ...
 NetIndia123.com1 month ago Biocon,TCS and PVR to see some action today  Indian-Commodity1 month ago Biocon gains after its subsidary Syngene files prospectus for IPO  Capital Market1 month ago Biocon subsidiary Syngene International files DRHP  Money Control1 month ago
NewsR.in

Asset sale lifts Biocon's profit

Biotech company Biocon reported 78 per cent growth in profit in the recent March quarter. This was largely on account of the exceptional gain on the sale of 10 per cent stake in Syngene International, Biocon's research services subsidiary, to IVF ...
 Hindu Business Line3 weeks ago Syngene Share Sale Boosts Biocon Profit  New Indian Express3 weeks ago Biocon Q4 consolidated net surges 78%  ZeeNews.com3 weeks ago Biocon Q4 consolidated net profit surges 78 per cent  Economic Times3 weeks ago
[x]  
India Infoline

Two drugs from Biocon-Mylan stable closer to pharmacies

Biotechnology major Biocon on Thursday said its partnership with Mylan has received a major boost with two molecules entering global Phase 3 clinical trials. The drug molecules are used to treat arthritis and cancer. Biocon and Mylan have ...
 Financial Express2 weeks ago Two Biocon biosimilar drugs enter global clinical trials  Livemint.com2 weeks ago
[x]  

Biocon, Mylan drug discovery programme makes progress

Pic Courtesy: - N New Delhi: On 7th May, Biocon said two molecules for treating cancer and arthritis under the drug discovery programme with Mylan have entered global Phase 3 of clinical trials. The molecules are Pegfilgrastim (PEG-G-CSF) and ...
 ZeeNews.com2 weeks ago Biocon, Mylan drug programme makes progress  Press Trust of India2 weeks ago
[x]  

Biocon plays its Syngene card

The article below represents a preview only and is not meant for reuse or republishing. Others MintAsia Magazines India, May 8 -- Companies like to put their best forward in the run-up to a listing. Biocon Ltd's research services subsidiary, ...
 HT Syndication2 weeks ago Biocon plays its Syngene card [Mint, New Delhi]  Bloomberg3 weeks ago
Prev | Next
Personalize your Realtimeclose [x]
Add content to your personalized tab - My News
Add upto 6 topics of your interest:
for eg.2g Scam , World
1.
2.
3.
4.
5.
6.
Personalize the tabs display. ( You can add or remove the tabs )
AlertsGet updates on latest news & your favourite topics right in your inbox.Set an Alert|Manage your Alerts

Get

Realtime News

on your Webpage

Add Widget >Get your members hooked!
Related Queries - biocon
    
Alerts
Get updated on latest news & your favorite topics right in your inbox!
 
More     Less